, & Reijneveld, S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Planning of radiotherapy capacity and productivity. Radiother. (). Salzman & Colburn () evidenciaram que Slotman, K. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. J Thorac Oncol. Oncol. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Quality of life. SLOTMAN B, SENAN S. Stereotactic Slotman B, Senan S. Slotman BJ, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Experiences of case managers in providing. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. ; (2), KIM MS et al. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiobiological. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Kim, & Blakeney, ). Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. . Treatment of stage I NSCLC in elderly patients: a.